Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CGON · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Un… NCT06443944 · Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside | CGON CG Oncology, Inc. | — | Available | — | — | Registry ↗ |
| Sep 3, 2026 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC NCT06567743 · High-Risk Non-Muscle-Invasive Bladder Cancer Cretostimogene Grenadenorepvec | CGON CG Oncology, Inc. | Phase 2 | Recruiting | 325 | Mar 31, 2027 | Registry ↗ |
| Jul 10, 2026 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to… NCT04452591 · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papil… Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside | CGON CG Oncology, Inc. | Phase 3 | Active, not recruiting | 190 | Jun 16, 2030 | Registry ↗ |
| Jul 1, 2026 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Followi… NCT06111235 · Non Muscle Invasive Bladder Cancer, Urologic Cancer Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside | CGON CG Oncology, Inc. | Phase 3 | Active, not recruiting | 367 | Nov 2026 | Registry ↗ |
| Apr 2, 2026 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasi… NCT02143804 · Bladder Cancer, High Grade oncolytic adenovirus expressing GMCSF | CGON CG Oncology, Inc. | Phase 2 | Withdrawn | 0 | Mar 2015 | Registry ↗ |
| Sep 25, 2024 | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unr… NCT04387461 · Non Muscle Invasive Bladder Cancer CG0070, Pembrolizumab Injection | CGON CG Oncology, Inc. | Phase 2 | Completed | 35 | Mar 7, 2023 | Registry ↗ |
| Apr 14, 2021 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure NCT02365818 · Bladder Cancer CG0070 | CGON CG Oncology, Inc. | Phase 2 | Completed | 66 | Aug 2018 | Registry ↗ |
| Apr 14, 2021 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer NCT01438112 · Transitional Cell Carcinoma, Bladder Cancer CG0070 Adenovirus Vector, Control Arm: Quadruple Choice | CGON CG Oncology, Inc. | Phase 2/3 | Terminated | 22 | Jun 2016 | Registry ↗ |
8 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances